Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment.

ABSTRACT:

Background

Atopic dermatitis (AD) is an inflammatory disorder characterized by dominant type 2 inflammation leading to chronic pruritic skin lesions, allergic comorbidities, and Staphylococcus aureus skin colonization and infections. S aureus is thought to play a role in AD severity.

Objectives

This study characterized the changes in the host-microbial interface in subjects with AD following type 2 blockade with dupilumab.

Methods

Participants (n = 71) with moderate-severe AD were enrolled in a randomized (dupilumab vs placebo; 2:1), double-blind study at Atopic Dermatitis Research Network centers. Bioassays were performed at multiple time points: S aureus and virulence factor quantification, 16s ribosomal RNA microbiome, serum biomarkers, skin transcriptomic analyses

SUBMITTER: Simpson EL 

PROVIDER: S-EPMC10716365 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature